Glass House Brands Inc.
GLASFDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Simvastatin | Phase 2 | Alzheimer's Disease | - | - |
Frequently asked questions
What is in Glass House Brands Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Glass House Brands Inc.'s (GLASF) pipeline across Phase 2. Its lead program is Simvastatin (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Glass House Brands Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Glass House Brands Inc. (GLASF) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track GLASF biotech catalysts?→
Add GLASF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Glass House Brands Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.